Trial Profile

Open Label Randomized Clinical Study of Plasmid Encoding p62/SQSTM1 (ELenagen) in in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 09 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs P62-cancer-dna-vaccine CureLab Oncology (Primary) ; Gemcitabine
Indications Ovarian cancer
Focus Therapeutic Use
Sponsors CureLab Oncology

Most Recent Events

27 Jul 2023 Status changed from recruiting to active, no longer recruiting.
02 Mar 2023 According to a CureLab media release, following impressive clinical data presented at the European Society for Medical Oncology Congress in Paris, the funds will enable CureLab Oncology to ramp up toward this FDA-monitored clinical trial in 2023.
15 Sep 2022 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com